Company Overview
Snapshot
Founded in March 2025 by Hanna Keller, Inhalify operates with 1–10 employees. The company has secured $83,000 across three funding rounds from investors including Technion Research & Development Foundation. In February 2025, Inhalify received a grant, underscoring its early-stage development and validation efforts in pediatric digital health.
Business overview
Inhalify is a pediatric digital health solution focused on monitoring and supporting inhaler use in children, particularly those under ten who use spacers. The company's core technology involves a sensor-based add-on device for standard inhalers and spacers, a mobile application for caregivers, and a clinician dashboard. This system measures air pressure, flow, and humidity to verify proper medication inhalation, providing real-time feedback. Data collected by the sensor is transferred to the mobile app, allowing parents and doctors to track adherence and inhalation patterns. Inhalify also incorporates an AI algorithm for asthma attack prediction, enabling proactive treatment adjustments. The company addresses a critical gap in pediatric respiratory care by monitoring spacer-based inhaler usage and is pursuing FDA 510k clearance, having conducted validation using artificial lung machines.
Log in to access full profile ›Company Intelligence Q&A
- What is Inhalify's primary focus in the healthcare sector?
- Inhalify specializes in pediatric digital health, developing solutions to monitor and improve the use of asthma inhalers and spacers in children, particularly those under the age of ten.
- When was Inhalify founded and by whom?
- Inhalify was founded in March 2025 by Hanna Keller.
- What is the core technology behind Inhalify's product?
- Inhalify utilizes a sensor-based add-on device that attaches to standard inhalers and spacers. This device measures air pressure, flow, and humidity to determine if a child has properly inhaled their prescribed medication dose.
- Has Inhalify received any grants or non-equity funding?
- Yes, Inhalify received a grant in February 2025. Additionally, in July 2023, the company received funding from Technion Research & Development Foundation, and in August 2024, it received funding from Road2.
- What regulatory steps is Inhalify taking for its product?
- Inhalify is undergoing regulatory planning and intends to pursue the 510k FDA track for its smart asthma inhaler system.